Background Fabry disease, an inherited lysosomal storage disorder, causes multi-organ
pathology resulting in substantial morbidity and a reduced life expectancy. Although Fabry …

Background Enzyme replacement therapy (ERT) with recombinant human α-galactosidase
has been available for the treatment of Fabry disease since 2001 in Europe and 2003 in the …

Fabry disease is an X-linked lysosomal multisystem storage disorder induced by a mutation
in the alpha-galactosidase A (GLA) gene. Reduced activity or deficiency of alpha …

Background Fabry's disease, an X-linked disorder of lysosomal α-galactosidase deficiency,
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …

Background Fabry disease is an X-linked lysosomal storage disorder caused by GLA
mutations, resulting in α-galactosidase (α-Gal) deficiency and accumulation of lysosomal …

Background Agalsidase β is a form of enzyme replacement therapy for Fabry disease, a
genetic disorder characterised by low α-galactosidase A activity, accumulation of …

OBJECTIVE In health, the rise in glucose after lunch is less if breakfast is eaten. We
evaluated the second-meal effect in type 2 diabetes. RESEARCH DESIGN AND METHODS …

Abstract Background The p. Asn215Ser or p. N215S GLA variant has been associated with
late‐onset cardiac variant of Fabry disease. Methods To expand on the scarce phenotype …

The competitive advantage of a company strongly depends on its possibility to benefit from
innovational activities. Understanding the factors that affect product and process innovation …

The rise in blood glucose after lunch is less if breakfast has been eaten. The metabolic basis
of this second-meal phenomenon remains uncertain. We hypothesized that storage of …